Liquid chromatography‐tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non‐small cell lung cancer patients
暂无分享,去创建一个
F. Goldwasser | L. Labat | M. Allard | B. Blanchet | A. Thomas-Schoemann | A. Bellesoeur | P. Boudou-Rouquette | M. Vidal | J. Alexandre | J. Chapron | F. Giraud | J. Arrondeau | Rafael Reis